

Chemical Safety Practices Recommendations

Aza-englerin

Exposure Hazards *

Category 2
Danger
Toxic



Response to Exposure

Oral	Dermal	Inhalation	Injection
Rinse mouth; do not induce vomiting. Report to OHS.	Wash skin with soap and water for 15 minutes. Rinse eyes for 15 minutes. Report to OHS.	Leave area; go to clean air. Report to OHS.	Report to OHS.
Special Precautions	These statements are based on the literature available for similar drugs. Aza-englerin is a novel compound and uncharacterized, the hazards of exposure may be greater than presented and all precautions should be taken to prevent exposure. Discard garments as hazardous if contaminated with Aza-englerin.		
Personal Protective Equipment	Gloves (Latex or Nitrile) Skin Protection (Suit or Scrubs or Lab Coat) Eye Protection (Safety-glasses or Goggles) Closed-toe shoes Use N100 respirator if engineering controls are not available.		
Engineering Controls	Aza-englerin powder- Chemical Fume Hood (CFH) (1) Aza-englerin solution- CFH or Biosafety Cabinet (Class II, B2 BSC if aerosolized) Animal waste and bedding until 10 days after last treatment- CFH or Class II, B2 BSC		
Animal Handling	Avoid exposure to animal waste until 10 days after last treatment.		
Bedding Disposal	Dispose of bedding as hazardous material until 10 days after last treatment.		
Work Practices	Empty Aza-englerin containers and unused Aza-englerin must be disposed of as hazardous. Follow LASP SOPs for preparation, handling, dosing, and disposal of Aza-englerin.		



* Hazard rating derived by applying safety factor (10) to Maximum Tolerable Dose (100mg/kg PO) (unpublished)

Inhalation of the smoke from the tree from which Englerin is extracted causes death.(2)

Therapeutic dosage may alter 'blood sugar' and/or insulin resistance. (3)

References:

- National Research Council Committee on Prudent Practices in the L. The National Academies Collection: Reports funded by National Institutes of Health. Prudent Practices in the Laboratory: Handling and Management of Chemical Hazards: Updated Version. Washington (DC): National Academies Press (US) National Academy of Sciences.; 2011.
- Beutler, inventor; The US, DHHS, NIH, Bethesda MD, assignee. Epoxy-Guaiane Derivatives and Treatment of Cancer. USA2010 11/11/2010.
- Sourbier C, Scroggins BT, Ratnayake R, Prince TL, Lee S, Lee MJ, et al. Englerin A stimulates PKC θ to inhibit insulin signaling and to simultaneously activate HSF1: pharmacologically induced synthetic lethality. Cancer cell. 2013;23(2):228-37.

Questions or concerns: Please contact EHS, Ted Witte, theodore.witte@nih.gov or 301-846-5860
Reviewed 12/26/2014 *These recommendations are not final and may be updated.*